Hypertension in adult Fabry's disease: Is cardiotrophin-1 a diagnostic biomarker?

Monica Gioia Marazzi, Emanuela Galliera, Elena Vianello, Elena Dozio, Andrea Stella, Guido Tettamanti, Lorenza Tacchini, Massimiliano M. Corsi Romanelli

Research output: Contribution to journalArticlepeer-review


Cardiotrophin-1 (CT-1), a cytokine produced by cardiomyocytes and non-cardiomyocytes in conditions of stress, can be used as a biomarker of left ventricular hypertrophy and dysfunction in hypertensive patients. Hypertension is one of the main adverse events in the third and last phase of Fabry's disease (FD). We measured CT-1 in order to examine its correlation with the vascular and cardiac alterations at different ages and assess its potential for use as a biomarker of hypertension in FD. Findings: The level of CT-1 was clearly higher in hypertensive adults than in adult FD patients. FD patients show a small, non-significant decrease in plasma CT-1 with age, while in hypertensive patients CT-1 in plasma rises strongly and highly significantly with age. Conclusions: CT-1 can be considered a good biomarker of the progression of hypertension with age, but particular care is needed when following hypertension in FD patients, since CT-1 does not correlate the same way with this disease.

Original languageEnglish
Article number27
JournalImmunity and Ageing
Issue number1
Publication statusPublished - Dec 20 2014


  • Cardiotrophin-1 (CT-1)
  • Fabry disease (FD)
  • Hypertension

ASJC Scopus subject areas

  • Immunology
  • Ageing


Dive into the research topics of 'Hypertension in adult Fabry's disease: Is cardiotrophin-1 a diagnostic biomarker?'. Together they form a unique fingerprint.

Cite this